novo nordisk glp-1 receptor agonist medications Market Overview: GLP-1 Agonists and the Obesity Market Glucagon-like peptide-1 receptor: mechanisms and
Description
Wang Y, Zhou Y, Wang Z, Ni Y, Prudhomme GJ, Wang Q
According to a 2024 study by Duo Do et al., reported that the use of a once-weekly GLP-1 receptor agonist was independently linked to a 30.5% higher prevalence of elevated residual gastric content on preprocedural gastric ultrasonography, which is a significant risk factor for aspiration during anesthesia
Reducing processed foods, sugar, and unhealthy fats is also crucial
Which is right for me
And in the randomized trials of these GLP-1 medications, about 14% to 38% of participants didn't achieve at least 5% weight loss
